WideCells Group

INTERVIEW: Widecells Group plc A cash generative, global proposition, all-star cast

Widecells Group plc (LON:WDC) CEO João Andrade talks to DirectorTalk about the company, how it plans to provide support advancements to the stem cell industry, the new laboratory in Manchester, the launch of CellPlan and João also explains why he has such a strong team on-board.

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry. With this in mind, it has created three divisions:

· CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process

· WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Center to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising on stem cell storage.

· WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

Share on:
Find more news, interviews, share price & company profile here for: